Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHAT | P28329 | 2/20 | 0.85 |
| ▸ | NAA50 | Q9GZZ1 | 2/20 | 0.85 |
| ▸ | EP300 | Q09472 | 4/20 | 0.84 |
| ▸ | KAT5 | Q92993 | 2/20 | 0.84 |
| ▸ | AURKA | O14965 | 2/20 | 0.84 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.84 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.79 |
| ▸ | NAA40 | Q86UY6 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1370748 | 1.00 | CHAT (0.85) | CHATNAA50EP300KAT5AURKA | |
| SCHEMBL30991360 | 1.00 | CHAT (0.85) | CHATNAA50EP300KAT5AURKA | |
| SCHEMBL20815907 | 1.00 | CHAT (0.85) | CHATNAA50EP300KAT5AURKA | |
| SCHEMBL26700227 | 0.96 | EP300 (0.83) | CHATNAA50EP300KAT5AURKA | |
| SCHEMBL28803301 | 0.96 | EP300 (0.83) | CHATNAA50EP300KAT5AURKA | |
| SCHEMBL28670397 | 0.95 | CHAT (0.83) | CHATNAA50EP300KAT5AURKA | |
| SCHEMBL29366032 | 0.95 | NAA50 (0.84) | CHATNAA50EP300KAT5AURKA | |
| SCHEMBL28017929 | 0.94 | EP300 (0.84) | CHATNAA50EP300KAT5AURKA | |
| SCHEMBL2112268 | 0.94 | CHAT (0.83) | CHATNAA50EP300KAT5AURKA | |
| SCHEMBL18608119 | 0.94 | CHAT (0.87) | CHATNAA50EP300KAT5AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4281058-B1 | FUNCTIONALIZED LONG-CHAIN DICARBOXYLIC ACIDS, AND THEIR USE FOR TREATMENT OF KIDNEY DISEASES | ESPERVITA THERAPEUTICS INC (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12396972-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | ESPERVITA THERAPEUTICS, INC. (US) | 2025-08-26 | — | — | US | disclosed |
| US-20240398737-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS, INC. | 2024-12-05 | — | — | US | disclosed |
| US-11737995-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | ESPERVITA THERAPEUTICS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11730712-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | ESPERVITA THERAPEUTICS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20230113853-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230113853-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | AHR, PKD1, CFTR | CHAT 750/4885NAA50 1994/4885EP300 1214/4885 |
| US-11737995-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | AHR, PKD1, CFTR | CHAT 760/4885NAA50 1738/4885EP300 1071/4885 |
| US-12396972-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | AHR, PKD1, CFTR | CHAT 750/4885NAA50 1994/4885EP300 1214/4885 |
| US-11730712-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | CPT1A, PPARG, PC | CHAT 450/4885NAA50 1445/4885EP300 689/4885 |
| US-20240398737-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | AHR, PKD1, CFTR | CHAT 750/4885NAA50 1994/4885EP300 1214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.